FDI India, a one-of-its-kind consultancy firm, is enabling pharma businesses by opening new avenues for foreign credit through the most credible route thereby enabling business growth. With FDI contributing significantly to the third largest sector setting India as the “Pharmacy of the World”, the Pharma sector is paving ways towards a growth projection of $100 billion by 2025.
The government’s concerted push towards the pharma sector through initiatives such as “Make in India”, Ayushman Bharat Scheme, National Digital Health Mission etc, the sector has emerged as a leading global capital market. With access to large consumer markets, generation of new employment opportunities, increase in research and development and rise in net foreign exchange earnings, the Indian as well as foreign businesses are betting big on the sector.
Commenting on the same, Mr Vishal Yadav, CEO & Founder, FDI India, said “The increasing FDI inflows is a reflection of the firm belief by global investors that India will lead as one of the major growth engines coupled with steady-state of market reforms. The pharma sector is well poised and is attracting FDI and exploiting the many opportunities that COVID 19 has created. We are helping businesses with financial strength by giving them the right kind of consultancy to obtain soft loans. With our interactive platform, we are handholding businesses in the investment lifecycle right from pre-investment to after-care with a view to simplifying the business environment for them.”
FDI India, with the largest network of global investors from across 15 countries, has been at the forefront in providing consultancy to hundreds of Indian businesses with a wide range of services including Financial Planning & assistance, connecting them to the right foreign investors and project planning. The company enables businesses to obtain soft loans with a minimum ticket size of INR 25 Cr at 3.25% per annum on reducing balance. – MB Bureau